SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EQUITY ARTICLE M impact

Cyclopharm reports record half-year revenue on 74% U.S. growth

Cyclopharm said half-year revenue hit a record, driven by 74% U.S. growth and improved gross margins. Company also named Technegas as the preferred agent in new international guidelines.

CYC

Story updates

02:24:03 AM UTC
SquawkNews
Record half-year revenue up 14% to AUD 17.5 million, driven by 74% U.S. growth and margin expansion. New international guidelines name Technegas as preferred agent, supporting accelerated U.S. adoption and expansion into broader indications.Based on Cyclopharm Limited [CYC] H1 2026 Audio Transcript…

Cyclopharm reported record half-year revenue up 14% to AUD 17.5 million, with 74% U.S. growth and margin expansion. The company said new international guidelines name Technegas as the preferred agent, supporting accelerated U.S. adoption and expansion into broader indications.

Based on Cyclopharm Limited [CYC] H1 2026 Audio Transcript…

Related stories